| Drug Name |
Pegvisomant |
| Drug ID |
BADD_D01699 |
| Description |
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity. |
| Indications and Usage |
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly. |
| Marketing Status |
approved |
| ATC Code |
H01AX01 |
| DrugBank ID |
DB00082
|
| KEGG ID |
D05394
|
| MeSH ID |
C406545
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0D6VE
|
| NDC Product Code |
0009-7166; 59267-5376; 59267-9301; 59267-9201; 0009-7168; 59267-5201; 59267-9401; 0009-7188; 0009-7200; 64052-001; 0009-7199 |
| UNII |
N824AOU5XV
|
| Synonyms |
pegvisomant | B2036-PEG | B-2036 PEG | Somavert |
